Pfizer's $43 Billion Seagen Deal to Revolutionize Cancer Therapy Delivery
TL;DR Summary
Pfizer CEO Albert Bourla said the company's $43 billion acquisition of Seagen will allow it to deliver Seagen's cancer therapy at a scale not seen before. Seagen is a leading developer of medicine called antibody-drug conjugates (ADCs), which are designed to kill cancer cells and spare healthy ones. The acquisition will bulk up Pfizer's cancer treatment portfolio, bringing four approved cancer therapies with combined sales of nearly $2 billion in 2022. Pfizer expects to complete the transaction later this year or in early 2024.
- Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal CNBC
- Pfizer Announces $43 Billion Deal for Cancer Drug Innovator Seagen Greek Reporter
- Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition? The Motley Fool
- Pfizer and Seagen bet on the future of cancer drugs Moneycontrol
- Analysis | Pfizer and Seagen Bet on the Future of Cancer Drugs The Washington Post
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
85%
571 → 84 words
Want the full story? Read the original article
Read on CNBC